Enhanced Therapeutic Combinations for Lowe Syndrome Treatment

The present inventive concept relates to improved therapeutic combinations for the treatment of Lowe Syndrome, enhancing the efficacy and safety of existing treatments by incorporating spatial regulation inhibitors, prenylation inhibitors, and specific statins and mTOR inhibitors.

Lowe Syndrome, a devastating genetic disease, is currently treated with limited efficacy using RhoA inhibitors, statins, and mTOR inhibitors. However, these treatments have inherent limitations, including variable efficacy, potential toxicity, and incomplete understanding of their mechanisms. The present inventive concept addresses these limitations by introducing novel combinations and formulations that improve cell migration and ciliogenesis, reduce cardiovascular risk, and enhance the overall treatment of Lowe Syndrome.

The inventive concept comprises a system for treating Lowe Syndrome, combining a RhoA inhibitor and a mTOR inhibitor, where the RhoA inhibitor is a spatial regulation inhibitor and the mTOR inhibitor is rapamycin or a rapamycin derivative. This combination is configured to improve cell migration and ciliogenesis in patients with Lowe Syndrome. Additionally, the inventive concept includes methods for enhancing the efficacy of RhoA inhibitors by administering them in combination with specific statins, such as rosuvastatin, atorvastatin, or simvastatin. Furthermore, the inventive concept encompasses pharmaceutical compositions and kits for treating Lowe Syndrome, incorporating prenylation inhibitors and specific mTOR inhibitors, such as everolimus or sirolimus, and formulated for oral administration.

The inventive concept's novelty lies in the specific combinations and formulations of RhoA inhibitors, statins, and mTOR inhibitors, which address the limitations of existing treatments and provide improved efficacy and safety. The inventive step resides in the identification of spatial regulation inhibitors, prenylation inhibitors, and specific statins and mTOR inhibitors that synergistically enhance the treatment of Lowe Syndrome.

Alternative embodiments of the inventive concept may include varying the specific types and amounts of RhoA inhibitors, statins, and mTOR inhibitors, as well as exploring different routes of administration and formulations. Additionally, the inventive concept could be adapted for treating other diseases or disorders characterized by impaired cell migration and ciliogenesis.

The inventive concept has significant commercial potential in the pharmaceutical industry, particularly in the area of rare genetic disease treatments. The market for Lowe Syndrome treatments is currently underserved, and the inventive concept's improved efficacy and safety profile make it an attractive solution for patients and healthcare providers.